RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Relapsing-Remitting Multiple Sclerosis Effectively Treated with Peginterferon Beta-1
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 6
SP 10
OP 11
DO 10.1177/155989771406006
UL http://mdc.sagepub.com/content/14/6/10.abstract
AB Significantly more subjects with relapsing-remitting multiple sclerosis achieved freedom from measured disease activity when treated with peginterferon beta-1a every 2 weeks compared with those who were treated with peginterferon beta-1a every 4 weeks or placebo. This article presents results from a post hoc analysis of 48-week data from the Efficacy and Safety Study of BIIB017 (PEGylated Interferon Beta-1a) in Participants With Relapsing Multiple Sclerosis trial [ADVANCE; NCT00906399].